Advertisement
YOU ARE HERE: LAT HomeCollectionsSymlin Drug
IN THE NEWS

Symlin Drug

FEATURED ARTICLES
BUSINESS
September 21, 2004 | Denise Gellene
Amylin Pharmaceuticals Inc. of San Diego said it had submitted new information to the Food and Drug Administration about Symlin in its 17-year quest to market the experimental injectable drug for diabetes. The FDA told Amylin in January that it was concerned about hypoglycemia, or low blood sugar, which can lead to nausea, confusion and brain injury.
ARTICLES BY DATE
BUSINESS
September 21, 2004 | Denise Gellene
Amylin Pharmaceuticals Inc. of San Diego said it had submitted new information to the Food and Drug Administration about Symlin in its 17-year quest to market the experimental injectable drug for diabetes. The FDA told Amylin in January that it was concerned about hypoglycemia, or low blood sugar, which can lead to nausea, confusion and brain injury.
Advertisement
BUSINESS
December 20, 2003 | From Bloomberg News
Amylin Pharmaceuticals Inc. said the Securities and Exchange Commission was conducting an informal inquiry related to communications about the company's Symlin injectable drug for blood-sugar control. The inquiry may be related to compliance with an SEC regulation on fair disclosure, the San Diego-based company said. The rule is aimed at curbing selective disclosure of material information to some people by requiring that information to be made public.
BUSINESS
December 18, 2003 | Denise Gellene, Times Staff Writer
Amylin Pharmaceuticals Inc. suffered a setback Wednesday when the Food and Drug Administration said it wouldn't approve the company's experimental diabetes drug without additional information. The San Diego firm has been developing the drug for 16 years. Called Symlin, it is a synthetic version of a natural hormone that works with insulin to regulate the flow of sugar from food into the bloodstream.
Los Angeles Times Articles
|